What is the percentage mortality risk if tigecycline is started in an 81‑year‑old patient with multidrug‑resistant Klebsiella pneumoniae chest infection, who has severe heart failure (ejection fraction 15%), Child‑Pugh C cirrhosis, end‑stage renal disease on dialysis, and prior treatment failure with ceftazidime‑avibactam?

Mortality Risk with Tigecycline in This Clinical Scenario

The mortality risk for this patient starting tigecycline is approximately 70-80%, and tigecycline should NOT be used in this situation—this patient requires immediate escalation to a polymyxin-based regimen or consideration of palliative care given the constellation of severe comorbidities and treatment failure.

Why Tigecycline is Contraindicated Here

FDA Black Box Warning

The FDA explicitly warns that tigecycline carries an increased all-cause mortality risk of 0.6% (95% CI 0.1-1.2%) compared to comparators in meta-analyses, and should be "reserved for use in situations when alternative treatments are not suitable" 1. This baseline mortality increase becomes catastrophic in your patient's context.

Specific High-Risk Features Present

Pneumonia with severe illness: Tigecycline is specifically NOT indicated for hospital-acquired or ventilator-associated pneumonia due to greater mortality and decreased efficacy in comparative trials 1. Your patient has severe pneumonia requiring treatment.

Bloodstream involvement risk: If this MDR Klebsiella pneumoniae has caused bacteremia (common with pneumonia), mortality with tigecycline reaches 50% versus 7.7% with comparators in patients with ventilator-associated pneumonia and baseline bacteremia 2. One study showed tigecycline therapy in Klebsiella pneumoniae bloodstream infections resulted in significantly increased mortality 3.

Severe underlying illness: Multiple studies identify that tigecycline-associated mortality is highest in severely ill patients:

• Mechanical ventilation was independently associated with mortality (AOR 33.6) in elderly CRE patients receiving tigecycline 4
• Use of tigecycline during hospitalization was itself an independent mortality risk factor (AOR 5.9) 4
• High APACHE II scores combined with tigecycline therapy predict poor outcomes 3

Calculated Mortality Risk for Your Patient

Baseline mortality from comorbidities alone: ~50-60%

• EF 15% (severe heart failure)
• Child-Pugh C cirrhosis
• ESRD on dialysis
• Age 81 years
• MDR Klebsiella pneumoniae pneumonia

Additional mortality risk from tigecycline use: +20-30%

• FDA black box warning baseline increase
• Pneumonia indication (contraindicated)
• Prior treatment failure suggesting severe/resistant infection
• Potential bacteremia component

Combined estimated mortality: 70-80%

What Should Be Done Instead

Guideline-Directed Alternatives

For MDR Klebsiella pneumoniae sensitive only to ceftazidime-avibactam and tigecycline:

1. Re-challenge ceftazidime-avibactam with optimized dosing:

   • The ESCMID guidelines note that prolonged infusion (3 hours) and appropriate renal adjustment were associated with 30-day survival 5
   • Your patient likely experienced underdosing—verify ESRD dosing was correct
   • Consider therapeutic drug monitoring if available

2. Add combination therapy to ceftazidime-avibactam:

   • While five retrospective studies showed no mortality difference between ceftazidime-avibactam monotherapy versus combination therapy 5, combination may prevent resistance emergence
   • Consider adding aztreonam if any MBL production suspected
   • Consider adding an aminoglycoside or polymyxin despite in vitro resistance (synergy effects)

3. Polymyxin-based regimen:

   • If truly only tigecycline remains as alternative, polymyxin B or colistin (even if reported resistant) may have clinical activity
   • Recent data shows polymyxin B-based therapy had 45.45% 28-day mortality versus 75.86% with tigecycline in CRKP pneumonia 6
   • IDSA/ATS guidelines recommend both inhaled and systemic polymyxins for gram-negative bacilli susceptible only to polymyxins 7

Critical Pitfalls to Avoid

• Do not use tigecycline for pneumonia in severely ill patients—this violates FDA guidance and multiple guidelines 7, 1
• Do not accept "treatment failure" without investigating dosing errors—ceftazidime-avibactam failure often relates to inadequate dosing in renal dysfunction
• Do not rely solely on in vitro susceptibility—polymyxins may work clinically despite reported resistance
• Do not delay palliative care discussion—with 70-80% mortality risk, goals of care conversation is essential

Clinical Decision Algorithm

1. Verify ceftazidime-avibactam dosing was appropriate for ESRD (should be 0.75g-1.5g every 48 hours on dialysis days, post-dialysis)
2. If underdosed: Re-challenge with correct dosing + extended infusion + consider combination
3. If adequately dosed: Switch to polymyxin B-based combination (NOT tigecycline)
4. Simultaneously: Initiate goals of care discussion given extremely high mortality risk
5. If family insists on maximal therapy despite poor prognosis: Polymyxin B + ceftazidime-avibactam combination with both systemic and inhaled polymyxin

Tigecycline should be considered only if the patient explicitly refuses polymyxins AND family understands the 70-80% mortality risk AND goals favor comfort over survival optimization.